Arcutis Other Stockholder Equity vs Total Current Liabilities Analysis
ARQT Stock | USD 13.04 1.33 11.36% |
Arcutis Biotherapeutics financial indicator trend analysis is way more than just evaluating Arcutis Biotherapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arcutis Biotherapeutics is a good investment. Please check the relationship between Arcutis Biotherapeutics Other Stockholder Equity and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcutis Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. For more information on how to buy Arcutis Stock please use our How to Invest in Arcutis Biotherapeutics guide.
Other Stockholder Equity vs Total Current Liabilities
Other Stockholder Equity vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arcutis Biotherapeutics Other Stockholder Equity account and Total Current Liabilities. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Arcutis Biotherapeutics' Other Stockholder Equity and Total Current Liabilities is 0.93. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Arcutis Biotherapeutics, assuming nothing else is changed. The correlation between historical values of Arcutis Biotherapeutics' Other Stockholder Equity and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Arcutis Biotherapeutics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Other Stockholder Equity i.e., Arcutis Biotherapeutics' Other Stockholder Equity and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | 0.93 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Other Stockholder Equity
Total Current Liabilities
Total Current Liabilities is an item on Arcutis Biotherapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Arcutis Biotherapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Arcutis Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arcutis Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcutis Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. For more information on how to buy Arcutis Stock please use our How to Invest in Arcutis Biotherapeutics guide.At this time, Arcutis Biotherapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 3.3 M in 2024, despite the fact that Enterprise Value Multiple is likely to grow to (1.43).
Arcutis Biotherapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Arcutis Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arcutis Biotherapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 107.0M | 298.3M | 408.2M | 449.3M | 341.4M | 260.7M | |
Other Current Liab | 3.7M | 15.5M | 25.1M | 27.7M | 33.2M | 16.7M | |
Total Current Liabilities | 5.2M | 22.6M | 33.3M | 37.8M | 46.7M | 23.4M | |
Total Stockholder Equity | (65.0M) | 270.6M | 297.7M | 209.6M | 88.7M | 121.4M | |
Net Tangible Assets | (65.0M) | 270.6M | 297.7M | 202.4M | 232.8M | 124.1M | |
Net Debt | (63.0M) | (60.1M) | (18.9M) | 148.9M | 117.5M | 123.4M | |
Retained Earnings | (66.3M) | (202.0M) | (408.3M) | (719.8M) | (981.9M) | (932.8M) | |
Accounts Payable | 1.4M | 7.1M | 7.4M | 8.8M | 12.0M | 6.1M | |
Cash | 63.3M | 65.1M | 96.4M | 53.6M | 88.4M | 64.4M | |
Non Current Assets Total | 538K | 5.4M | 5.4M | 11.9M | 10.9M | 11.5M | |
Cash And Short Term Investments | 101.3M | 284.4M | 387.1M | 409.6M | 271.9M | 237.1M | |
Common Stock Shares Outstanding | 38.1M | 35.7M | 49.4M | 55.0M | 69.3M | 44.6M | |
Short Term Investments | 37.9M | 219.4M | 290.6M | 355.9M | 183.5M | 172.7M | |
Liabilities And Stockholders Equity | 107.0M | 298.3M | 408.2M | 449.3M | 341.4M | 260.7M | |
Non Current Liabilities Total | 166.8M | 5.0M | 77.1M | 201.9M | 206.0M | 115.9M | |
Capital Surpluse | 289K | 1.2M | 472.6M | 706.2M | 812.2M | 852.8M | |
Other Current Assets | 5.2M | 7.9M | 15.7M | 11.8M | 19.6M | 20.6M | |
Other Stockholder Equity | (165.2M) | 472.6M | 706.2M | 930.4M | 1.1B | 1.1B | |
Total Liab | 172.0M | 27.6M | 110.5M | 239.7M | 252.7M | 139.3M | |
Net Invested Capital | (65.0M) | 270.6M | 370.0M | 407.4M | 290.5M | 195.6M | |
Total Current Assets | 106.5M | 292.8M | 402.8M | 437.4M | 330.4M | 255.3M | |
Net Working Capital | 101.2M | 270.2M | 369.4M | 399.6M | 283.8M | 231.9M | |
Non Current Liabilities Other | 184K | 5.0M | 4.8M | 849K | 976.4K | 927.5K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.